Anders Lehmann

Göteborgs Stads — Sweden

Medicine · Health Sciences

29h-index4.0kcitations90works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Gastroesophageal reflux and treatments(27), Neuroscience and Neuropharmacology Research(26), Helicobacter pylori-related gastroenterology studies(16), Aldose Reductase and Taurine(16), Neuroscience of respiration and sleep(11)

Publications90 total

A Proof-of-Concept Study on the Effects of STA363 on Low Back Pain in Patients with Degenerative Disc Disease
Spine·2025
Intradiscal Administration of STA363 In Patients With Radiculopathy Caused by Lumbar Disc Herniation Reduces Disc Volume Predictive of Symptomatic Relief
Journal of Pain·2025
[Retrograde cricopharyngeal dysfunction (inability to belch) - a »new« diagnosis that deserves attention].
PubMed·2024
Translational Studies on Biologic Fusion of a Vertebral Segment as a Novel Treatment Modality for Low Back Pain
Spine·2020
Weight Perturbation Alters Leptin Signal Transduction in a Region-Specific Manner throughout the Brain
PLoS ONE·2017· 19 citedOpen Access
Discovery of New Drugs for Weight Loss and Prevention of Weight Regain
2016
Reducing Adverse Effects During Drug Development: The Example of Lesogaberan and Paresthesia
Clinical Therapeutics·2016· 3 cited
Intestinal SGLT1 in metabolic health and disease
American Journal of Physiology-Gastrointestinal and Liver Physiology·2016· 96 cited
Targeting the GABAB Receptors for the Treatment of Gastroesophageal Reflux Disease and Chronic Cough
2016· 5 cited
[Wrong thinking in theory resulted in potent drug in practice].
PubMed·2015
Effects of a novel MC4R agonist on maintenance of reduced body weight in diet‐induced obese mice
Obesity·2013· 15 citedOpen Access
Delineation of the GPRC6A Receptor Signaling Pathways Using a Mammalian Cell Line Stably Expressing the Receptor
Journal of Pharmacology and Experimental Therapeutics·2013· 73 citedOpen Access
Discovery of Agonists of Cannabinoid Receptor 1 with Restricted Central Nervous System Penetration Aimed for Treatment of Gastroesophageal Reflux Disease
Journal of Medicinal Chemistry·2012· 19 citedOpen Access
Antitussive effects of the peripherally restricted GABAB receptor agonist lesogaberan in guinea pigs: Comparison to baclofen and other GABAB receptor-selective agonists
Cough·2012· 24 citedOpen Access
Translational gastrointestinal pharmacology in the 21st century: ‘the lesogaberan story’
Current Opinion in Pharmacology·2011· 22 cited
4-Aminobutyrate Aminotransferase (ABAT): Genetic and Pharmacological Evidence for an Involvement in Gastro Esophageal Reflux Disease
PLoS ONE·2011· 11 citedOpen Access
The novel, peripherally restricted GABAB receptor agonist lesogaberan (AZD3355) inhibits acid reflux and reduces esophageal acid exposure as measured with 24-h pHmetry in dogs
European Journal of Pharmacology·2010· 24 cited
GABAB Receptor Agonism as a Novel Therapeutic Modality in the Treatment of Gastroesophageal Reflux Disease
Advances in pharmacology·2010· 31 cited
(R)-(3-Amino-2-fluoropropyl) Phosphinic Acid (AZD3355), a Novel GABAB Receptor Agonist, Inhibits Transient Lower Esophageal Sphincter Relaxation through a Peripheral Mode of Action
Journal of Pharmacology and Experimental Therapeutics·2009· 55 cited
M1910 Differentiating Features of Two Groups of GABAB Receptor Agonists As Reflux Inhibitors
Gastroenterology·2009Open Access
page 1 of 5Next →

Frequent Co-authors

Henrik Hagberg(10), Anders Hamberger(9), Jan P. Mattsson(8), Jörgen Jensen(8), Mats Sandberg(6), L. Ashley Blackshaw(6), Lena Brändén(5), Lillevi Kärrberg(4), Karolina Nilsson(4), Ingemar Jacobson(3), Peter Andiné(3), Madeleine Antonsson(3), Marianne Bremner‐Danielsen(3), Hans Bräuner‐Osborne(3), Jerzy W. Łazarewicz(3), Britta Nyström(2), Lena Hansson-Brändén(2), A. Edlund(2), A. Jonas Ekstrand(2), Susanne Elg(2)